August 2012

 

In this Supplement

Innovations in The Art of Stent Grafting

Utilizing the GORE® VIABAHN® Endoprosthesis to treat complex SFA and iliac artery disease.

Issue

Supplement

Download a PDF of this supplement

Technical Considerations for Achieving Success With the GORE® VIABAHN® Endoprosthesis

Thought leaders in the field weigh in on the key aspects of this device at the GORE® VIABAHN® Endoprosthesis Forum.

By Renée J. Robillard, MA, ELS

The Importance of Accurate Femoropopliteal Artery Sizing in Endovascular Therapy

Recognizing the current shortcomings of vessel measurement standards.

By Richard R. Saxon, MD, FSIR

Techniques for Achieving Long-Term Secondary Patency

Occlusion failure modes for stent grafts, treatment approaches, and expected outcomes.

By Charlie C. Cheng, MD; Lorraine Choi, MD; Zulfiqar Cheema, MD; and Michael B. Silva Jr, MD, FACS

Covered Stenting for Iliac Artery Occlusive Disease

Increasing evidence points to first-line use of covered stent grafts for complex iliac artery occlusive disease.

By Lee J. Goldstein, MD, FACS, CWS

Treating TASC II D Lesions With the GORE® VIABAHN® Endoprosthesis

Examining the evidence for treating long SFA disease with stent grafts.

By Peter A. Soukas, MD, FACC, FSVM, FSCAI

Collateral Arteries: To Cover or Not to Cover?

Our center’s experience using the GORE® VIABAHN® Endoprosthesis for treating long, diffuse SFA disease.

By Amir Motarjeme, MD
 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.